Core Insights - Edesa Biotech's CEO, Dr. Par Nijhawan, has been selected to present at the ATS 2026 Respiratory Innovation Summit, highlighting the significance of the Phase 3 results for paridiprubart in treating ARDS patients [1][3] Group 1: Presentation and Study Results - Dr. Nijhawan's presentation will focus on findings from the Phase 3 study of paridiprubart (EB05), an anti-TLR4 antibody for Acute Respiratory Distress Syndrome (ARDS), which leads to over three million ICU admissions globally each year [2] - The Phase 3 results include data from an initial 104 patients requiring invasive mechanical ventilation and expanded results from a broader 278-patient population, reinforcing the potential clinical benefits of paridiprubart [2] Group 2: Upcoming Events - The presentation by Dr. Nijhawan is scheduled for May 15, 2026, with an accompanying poster presentation by Edesa's research team at the summit [3] - Ted Steiner, MD, will present a full oral presentation of the Phase 3 results on May 20, 2026, during the ATS 2026 International Conference, focusing on the study's design and outcomes [4] Group 3: Product Overview - Paridiprubart is a new class of host-directed therapeutics designed to modulate the immune response against various health threats, including infectious diseases and other public health emergencies [5] - The drug works by inhibiting toll-like receptor 4 (TLR4), which is activated by various pathogens and is involved in chronic autoimmune diseases [5] Group 4: Company Background - Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on innovative treatments for inflammatory and immune-related diseases, with a pipeline that includes therapies for both medical dermatology and respiratory conditions [6] - The company is developing EB06 for vitiligo and EB01 for allergic contact dermatitis, alongside its lead respiratory candidate, paridiprubart, which is supported by funding from the Government of Canada [6]

Core Insights - Edesa Biotech, Inc. has announced that its CEO, Dr. Par Nijhawan, will deliver the inaugural presentation at the ATS 2026 Respiratory Innovation Summit, highlighting the significance of the company's Phase 3 study results for paridiprubart, an anti-TLR4 antibody for treating Acute Respiratory Distress Syndrome (ARDS) [1][2][3] Company Overview - Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, with a clinical pipeline targeting Medical Dermatology and Respiratory conditions [6] - The company is developing paridiprubart (EB05) as a treatment for ARDS, a condition that leads to over three million ICU admissions globally each year [2][6] Clinical Study Details - The Phase 3 study of paridiprubart has reported results from an initial cohort of 104 patients requiring invasive mechanical ventilation, followed by expanded results from a total of 278 patients, indicating potential clinical benefits [2] - Dr. Ted Steiner, the principal investigator of the Phase 3 study, will present comprehensive results at the ATS 2026 International Conference on May 20, 2026 [4] Presentation Significance - Dr. Nijhawan expressed that being invited to lead the innovation showcase is a validation of the strength of the Phase 3 data and the potential of paridiprubart to transform ARDS treatment, which currently has limited effective options [3] Therapeutic Mechanism - Paridiprubart represents a new class of host-directed therapeutics designed to modulate the immune response against various public health threats, including infectious diseases and other emergencies [5]

Core Viewpoint - Edesa Biotech, Inc. is advancing its Phase 2 clinical study of EB06 for moderate-to-severe nonsegmental vitiligo, with enrollment expected to begin mid-2026, following the selection of JSS Medical Research as its clinical research organization [1][2][3] Company Overview - Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for immuno-inflammatory diseases, with a pipeline that includes EB06 for vitiligo and other assets for allergic contact dermatitis and respiratory conditions [7][8] Clinical Study Details - The Phase 2 study will assess the safety and efficacy of EB06 compared to placebo in adults with non-segmental vitiligo, involving intravenous infusions during the treatment period followed by a follow-up [4] - Site activations and patient recruitment for the clinical trial are anticipated to start in mid-2026, with initial sites located in Canada [2] Drug Mechanism and Background - EB06 is a monoclonal antibody targeting chemokine ligand 10 (CXCL10), which is implicated in the autoimmune response in vitiligo by promoting the trafficking of anti-melanocytic T-cells and inducing melanocyte apoptosis [5][6] - Preclinical studies have shown that EB06 can prevent and reverse depigmentation, demonstrating pharmacodynamic activity necessary to address the immune dysfunction associated with vitiligo [5] Vitiligo Overview - Vitiligo is a chronic autoimmune condition affecting 0.5% to 2% of the global population, characterized by unpredictable loss of skin pigmentation, often beginning before the age of 20 [6]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential opportunities for traders [1] Premarket Gainers - Brand Engagement Network, Inc. (BNAI) is up 20% at $51.61 [3] - Latham Group, Inc. (SWIM) is up 20% at $7.79 [3] - Evolus, Inc. (EOLS) is up 14% at $4.74 [3] - Edesa Biotech, Inc. (EDSA) is up 11% at $4.86 [3] - 20/20 Biolabs, Inc. (AIDX) is up 11% at $3.28 [3] - DeFi Development Corp. (DFDV) is up 9% at $4.04 [3] - Accel Entertainment, Inc. (ACEL) is up 7% at $11.95 [3] - Solana Company (HSDT) is up 7% at $2.12 [3] - Nano-X Imaging Ltd. (NNOX) is up 6% at $2.76 [3] - Strive Asset Management, LLC (ASST) is up 5% at $8.81 [3] Premarket Losers - Battalion Oil Corporation (BATL) is down 28% at $19.67 [4] - TMD Energy Limited (TMDE) is down 24% at $3.03 [4] - Ascent Industries Co. (ACNT) is down 15% at $14.75 [4] - indie Semiconductor, Inc. (INDI) is down 14% at $2.71 [4] - WEBTOON Entertainment Inc. (WBTN) is down 13% at $9.98 [4] - STAAR Surgical Company (STAA) is down 10% at $17.00 [4] - Indonesia Energy Corporation Limited (INDO) is down 10% at $4.68 [4] - BiomX Inc. (PHGE) is down 7% at $4.52 [4] - Arbutus Biopharma Corporation (ABUS) is down 6% at $4.37 [4] - Global Interactive Technologies, Inc. (GITS) is down 6% at $2.43 [4]

Investment Rating - The report indicates a positive investment outlook for the prostate cancer treatment sector, particularly focusing on PSMA-targeted therapies, with a strategic partnership between Vir Biotechnology and Astellas valued at $1.7 billion [12][16]. Core Insights - Prostate cancer is one of the most common malignancies in men globally, with PSMA being a critical biomarker for diagnosis and treatment. PSMA-targeted therapies, including radioligand therapy and novel T-cell engagers, show significant promise in treating advanced stages of the disease [8][11]. - The report highlights the advancements in PSMA/CD3 T-cell engagers (TCEs), particularly the development of VIR-5500 and JANX007, which utilize shielding peptide technology to enhance safety and efficacy by limiting T-cell activation to the tumor microenvironment [11][20][29]. - Initial clinical data for VIR-5500 shows good tolerability and promising efficacy, with a PSA response rate of 82% in high-dose groups, indicating a strong potential for further development [25][21]. Summary by Sections Section 1: Prostate Cancer and PSMA Targeting - PSMA is highly expressed in prostate cancer cells, making it a key target for both diagnostic and therapeutic interventions. The dual enzymatic activity of PSMA supports its role in promoting tumor aggressiveness [8][9]. - Current PSMA-targeted strategies include radioligand therapies and novel TCEs, which are being actively researched and developed [8][11]. Section 2: Clinical Development of PSMA/CD3 TCEs - The report details the clinical progress of PSMA/CD3 TCEs, noting that early candidates faced challenges due to issues like antibody-drug interactions and systemic toxicity. However, the introduction of shielding peptide technology has shown potential to mitigate these risks [11][12]. - VIR-5500, a leading candidate, has shown positive early-phase clinical trial results, with a strategic partnership established to support its development [16][21]. Section 3: Company Updates and Financials - Vir Biotechnology has secured a $335 million upfront payment from Astellas as part of their collaboration, with potential milestone payments reaching up to $1.37 billion [16][12]. - The report also mentions the financial performance of various biotech companies, highlighting significant revenue growth and strategic partnerships that enhance their market positions [45].

Core Viewpoint - Edesa Biotech, Inc. has announced positive results from a Phase 3 study of paridiprubart, demonstrating significant reductions in 28-day mortality across a broad patient population, which has led to increased stock performance and interest in the company's therapeutic potential [1][2][3]. Study Results - The Phase 3 study included a total of 278 patients, combining previously reported 104 patients requiring invasive mechanical ventilation (IMV) and 174 non-IMV patients [3][4]. - Paridiprubart reduced adjusted 28-day mortality from 33% to 24%, representing a 27% relative reduction in the risk of death (p<0.001) [4]. - In a subgroup of 174 patients not requiring IMV, paridiprubart + standard of care (SOC) reduced adjusted 28-day mortality from 23% to 15%, a 35% relative reduction (p<0.05) [5]. Safety and Efficacy - The safety profile of paridiprubart was consistent with prior clinical exposures, with low rates of adverse events and serious adverse events similar to the placebo group [6]. - Exploratory analyses indicated consistent reductions in adjusted mortality for paridiprubart + SOC compared to placebo + SOC across patients with significant comorbidities [6]. Intellectual Property and Future Plans - Edesa has filed provisional patent applications for the use of paridiprubart in treating sepsis, acute kidney injury, and pneumonia, with core patents extending into the 2030s [7]. - The CEO emphasized the potential of paridiprubart to address multiple critical unmet medical needs and mentioned ongoing regulatory discussions and strategic collaborations to accelerate development [9].

Core Insights - Edesa Biotech, Inc. announced positive results from a Phase 3 study of paridiprubart, demonstrating a significant reduction in 28-day mortality across a broad patient population [1][2][3] Study Results - The study involved 278 patients, including 104 requiring invasive mechanical ventilation (IMV) and 174 non-IMV patients, showing a 27% relative reduction in mortality from 33% to 24% (p<0.001) [2][3] - In a subgroup of 174 non-IMV patients, paridiprubart reduced mortality from 23% to 15%, a 35% relative reduction (p<0.05) [4] - Exploratory analyses indicated consistent mortality reductions in patients with serious comorbidities, with overall adverse events being low and similar between treatment groups [5] Patent and Regulatory Developments - Edesa has filed provisional patent applications for paridiprubart's use in treating sepsis, acute kidney injury, and pneumonia, with core patents extending into the 2030s [6] - The company is advancing regulatory discussions and exploring strategic collaborations to accelerate development and broaden access [8] Future Studies and Presentations - Paridiprubart is being evaluated in a separate U.S. government-funded study with enrollment ongoing for approximately 200 subjects [9] - Edesa has been selected for an oral presentation at the ATS 2026 conference to share additional findings from the Phase 3 study [12] Mechanism and Background - Paridiprubart is a first-in-class anti-TLR4 antibody designed to modulate the immune response in various critical conditions, including ARDS, which has high mortality rates and limited treatment options [19][20] - ARDS accounts for 10% of ICU admissions globally, representing over 3 million patients annually [20] Company Overview - Edesa Biotech focuses on developing innovative treatments for inflammatory and immune-related diseases, with a clinical pipeline that includes both medical dermatology and respiratory therapeutic areas [21]

Financial Performance - Net loss was $2.2 million, or $0.28 per common share, for the three months ended December 31, 2025, compared to a net loss of $1.6 million, or $0.48 per common share for the same period in 2024[98]. - Total operating expenses increased by $0.4 million to $2.3 million for the three months ended December 31, 2025, compared to $1.9 million for the same period last year[95]. - The company had an accumulated deficit of $68.2 million and working capital of $12.0 million, including $12.1 million in cash and cash equivalents as of December 31, 2025[110]. - The company expects to continue incurring substantial operating losses as it develops product candidates and seeks marketing approval[111]. Cash Flow - Net cash used in operating activities was $2.1 million for the three months ended December 31, 2025, compared to $1.5 million for the same period in 2024[101]. - Net cash provided by financing activities was $3.4 million for the three months ended December 31, 2025, compared to $2.1 million for the same period in 2024[114]. - Cash and cash equivalents at the end of the quarter were $12.1 million, compared to $10.8 million as of September 30, 2025[101]. Research and Development - Research and development (R&D) expenses increased by $0.1 million to $1.1 million for the three months ended December 31, 2025, primarily due to increased expenses for manufacturing-related activities[95]. - R&D expenses increased to $1.1 million for the three months ended December 31, 2025, compared to $1.0 million for the same period in 2024, primarily due to manufacturing-related activities[116]. - EB05, a drug candidate for Acute Respiratory Distress Syndrome, met primary and secondary endpoints in a Phase 3 clinical study, showing clinically meaningful improvement in survival and recovery[92]. - EB06, an anti-CXCL10 monoclonal antibody candidate, is in discussions for a Phase 2 proof of concept study in patients with moderate-to-severe nonsegmental vitiligo, with enrollment anticipated by midyear 2026[90]. - The company is pursuing additional uses for paridiprubart in chronic diseases and is eligible for reimbursement of certain development expenses from the Government of Canada[92]. Financing Activities - The company sold 1,177,568 common shares for net proceeds of approximately $3.4 million under the At The Market Offering Agreement during the three months ended December 31, 2025[93]. - The company sold an aggregate of 834 Series B-1 Preferred Shares and 3,468,746 common shares for gross proceeds of approximately $15.0 million in a private placement[102]. - The company filed a shelf registration statement allowing for the offer and sale of up to $150.0 million of securities, effective September 9, 2025[103]. - The company plans to seek additional financing through equity sales, government grants, and potential strategic transactions to fund operations and product development[111]. Administrative Expenses - General and administrative (G&A) expenses increased by $0.3 million to $1.2 million for the three months ended December 31, 2025, primarily due to an increase in noncash share-based compensation[97]. - The company recorded grant income of $0.1 million for the three months ended December 31, 2025, a decrease from $0.3 million in the same period last year[105]. Off-Balance Sheet Arrangements - The company has no off-balance sheet arrangements that could materially affect its financial condition[117].

Financial Performance - For the first quarter ended December 31, 2025, Edesa reported a net loss of $2.2 million, or $0.28 per common share, compared to a net loss of $1.6 million, or $0.48 per common share for the same period in 2024[6]. - Total operating expenses increased by $0.4 million to $2.3 million for the three months ended December 31, 2025, compared to $1.9 million for the same period in the previous year[5]. - General and administrative expenses increased by $0.3 million to $1.2 million for the three months ended December 31, 2025, primarily due to an increase in noncash share-based compensation[8]. - The company reported a decrease in total other income by $0.2 million to $0.1 million for the three months ended December 31, 2025, primarily due to reduced reimbursement funding from the Canadian government's Strategic Response Fund[5]. Research and Development - Research and development expenses rose by $0.1 million to $1.1 million for the three months ended December 31, 2025, primarily due to increased manufacturing-related activities[8]. - Edesa is exploring accelerated commercialization pathways for its monoclonal antibody paridiprubart following positive Phase 3 study results[4]. - Edesa plans to present its Phase 3 respiratory and subgroup data at upcoming scientific and medical conferences[3]. - The company plans to begin recruitment for its Phase 2 study in moderate-to-severe nonsegmental vitiligo by midyear 2026, subject to regulatory approvals[3]. Financial Position - Edesa had cash and cash equivalents of $12.1 million and working capital of $12.0 million as of December 31, 2025[7]. - Total assets increased to $14.7 million as of December 31, 2025, compared to $13.5 million as of September 30, 2025[15].

Core Viewpoint - Edesa Biotech, Inc. is advancing its clinical programs, particularly in dermatology and respiratory diseases, while reporting a net loss for the first quarter of 2026, reflecting ongoing investments in drug development and manufacturing [1][5]. Financial Performance - Total operating expenses increased by $0.4 million to $2.3 million for the three months ended December 31, 2025, compared to $1.9 million for the same period in the previous year [4]. - Edesa reported a net loss of $2.2 million, or $0.28 per common share, for the quarter ended December 31, 2025, compared to a net loss of $1.6 million, or $0.48 per common share, for the same quarter in 2024 [5][13]. - Cash and cash equivalents at December 31, 2025, were $12.1 million, with working capital of $12.0 million [6]. Drug Development Progress - Edesa is progressing with the manufacturing of its dermatology drug candidate, EB06, for a Phase 2 study in moderate-to-severe nonsegmental vitiligo, with recruitment expected to begin midyear 2026, pending regulatory approvals [2][3]. - The company is evaluating subgroup data for additional efficacy signals in its respiratory program following positive results from a Phase 3 study of paridiprubart in patients with Acute Respiratory Distress Syndrome [2][3]. Research and Development - Research and development expenses increased by $0.1 million to $1.1 million for the three months ended December 31, 2025, primarily due to increased manufacturing-related activities for the EB06 program [7]. - General and administrative expenses rose by $0.3 million to $1.2 million for the same period, mainly due to an increase in noncash share-based compensation [7]. Upcoming Events - Edesa plans to participate in several upcoming scientific and medical conferences, including the Global Vitiligo Foundation Annual Scientific Symposium on March 26, 2026, and the American Thoracic Society 2026 International Conference from May 15-20, 2026 [8].